Compare VERU & MKTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | MKTW |
|---|---|---|
| Founded | 1971 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 39.7M |
| IPO Year | 1996 | 2020 |
| Metric | VERU | MKTW |
|---|---|---|
| Price | $2.99 | $16.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | $20.00 |
| AVG Volume (30 Days) | ★ 5.2M | 11.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 10.20% |
| EPS Growth | N/A | ★ 1183.33 |
| EPS | ★ N/A | N/A |
| Revenue | $16,296,958.00 | ★ $512,403,000.00 |
| Revenue This Year | N/A | $1.52 |
| Revenue Next Year | N/A | $4.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $13.49 |
| 52 Week High | $7.33 | $21.74 |
| Indicator | VERU | MKTW |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 44.94 |
| Support Level | $2.11 | $16.17 |
| Resistance Level | $4.57 | $17.69 |
| Average True Range (ATR) | 0.25 | 0.58 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 28.68 | 16.97 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.